Myeloma Matters: Prevention and Management of Bispecific Antibody–Associated Adverse Events in Multiple Myeloma

Project Oncology®

Innehåll tillhandahållet av ReachMD. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av ReachMD eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.

3M ago

MP3•Episod hem

Host: Jesus G. Berdeja, MD
Guest: Nicholas G. Barkemeyer, MPAS
Guest: Ajai Chari, MD
Guest: Harvey Church
Guest: Amy Gebhardt
Guest: Steven Morrow
Release date: 7/18/2024
Expiration date: 7/18/2025
Estimated time to complete: 1.0 hour

This activity is not accredited for CME/CE credit.

This episode of Myeloma Matters features discussions of bispecific antibody therapy, a powerful form of targeted immunotherapy that has produced high response rates and helped patients—even those with multiply relapsed or refractory multiple myeloma (RRMM)—achieve deeper and more sustained responses. This podcast will also review strategies for preventing and managing the serious, potentially life-threatening, adverse events (AEs) associated with myeloma bispecific antibody therapy, which include cytokine release syndrome (CRS), neurotoxicity, and infection.

156 episoder

#Oncology #Obstetrics And Gynecology #Oncology And Hematology #Omnia Education #Cme/ce #Oncology Power Hour #ReachMD #Women's Health #Women's Health Fridays™ #Science #Medicine #Health and Well-Being #Project Oncology®